Skip to main content
    A

    Axsome Therapeutics Inc (AXSM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $141.69
    -2.68 (-1.86%)

    Market Cap: $7.45B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Axsome Therapeutics Inc (AXSM) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Axsome Therapeutics (AXSM) to earn -$2.53 per share in the fiscal year ending Dec 31, 2026, on revenue of $952.18M. Of 22 analysts, 21 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $3.38.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 22 ratings average 1.91, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 95% of the ratings.

    RatingAnalystsShare
    Strong Buy313.6%
    Buy1881.8%
    Hold14.5%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    22

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 52.3%.

    Fiscal year ending Dec 31, 2026
    -$2.53
    EPS consensus, revenue $952.18M
    Fiscal year ending Dec 31, 2027
    $3.38
    EPS consensus, revenue $1.45B
    Next report
    Feb 10, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$2.53-$3.33 to -$0.6813$952.18M$928.10M to $996.29M21
    Dec 31, 2027$3.38$0.93 to $7.2513$1.45B$1.31B to $1.74B21

    Quarterly Estimates

    The EPS consensus rises from -$0.01 for the quarter ending Dec 31, 2026 to $0.03 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.01-$0.53 to $0.6724$291.88M$254.50M to $343.35M23
    Mar 31, 2027$0.03-$0.21 to $0.272$297.49M$277.20M to $335.47M7

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 5 upward and 6 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202746
    Quarter ending Mar 31, 202710

    EPS Trend

    The EPS consensus for the fiscal year ending Dec 31, 2026 is where it was 90 days ago.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$2.53-$2.43-$2.77-$2.64-$2.53N/A
    Fiscal year ending Dec 31, 2027$3.38$3.69$4.66$5.03$5.05-33.1%
    Quarter ending Mar 31, 2027$0.03-$0.34$0.16$0.12$0.30-89.9%

    Frequently Asked Questions About AXSM

    What is the AXSM stock forecast?

    Consensus analyst estimates put Axsome Therapeutics's EPS at -$2.53 for the fiscal year ending Dec 31, 2026, on revenue of $952.18M. The consensus rating from 22 analysts is Buy.

    How do analysts rate AXSM stock?

    Of 22 analysts covering Axsome Therapeutics, 3 rate it Strong Buy, 18 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from AXSM next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.53, with estimates from -$3.33 to -$0.68 from 13 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.38, with estimates from $0.93 to $7.25 from 13 analysts.

    What revenue do analysts expect from Axsome Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $952.18M, with estimates from $928.10M to $996.29M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.45B, with estimates from $1.31B to $1.74B.

    How many analysts cover AXSM?

    22 analysts rate Axsome Therapeutics stock, and 13 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.